Composition :

Each capsule ACETRO® contain Diacerein 50 mg


Pharmacology :

Diacerein is an anti-osteoarthritis drug and anti-inflammation for degenerative joint disease (osteoarthritis and other related diseases).

In-vitro and in-vivo study, Diacerein show that it has efficacy as anti-osteoarhtritis and stimulate the cartilage, together with anti-inflammation drugs. It has specific mechanism and it did not inhibition prosteoglandin sintesis.

Effect from Diacerein will build up after 2-4 weeks therapy. Significant improvement has been shown after 4-8 weeks therapy, and this effect has been shown until 2 months therapy stopped (carry-out effect). Combination therapy with analgesic or NSAID could be recommended for 2-4 weeks therapy.


Indication :

Long symptomatic treatment on osteoarthritis.


Dosage :

1 capsule twice daily with main menu for long therapy (not less than 6 months). For the first therapy for 4 weeks, it recommended to take 1 capsule daily by oral with dinner. Because Diacerein increase gastrointestinal transit time for 4 weeks first therapy. If this patient has a good tolerance, dosage may be increased become 2 capsules daily, by oral and with food.

The Doctor must suggest the duration therapy for a good results. But, the duration therapy is not less than 6 months.

For long treatment with other drugs, should be checked the complete blood, included liver enzymes, and urine every 6 months.

Related with the late onset from Diacerein (2-4 weeks after therapy), Diacerein could be related with concomitant use NSAIDs (non-steroid anti-inflammatory drugs) or analgesics in 2-4 weeks first therapy.


It do not have clinical data for children. Diacerein is not recommended for children because it has not been known the safety profile and the efficacy.


It is not need change the dosage on elderly people.

Renal insufficiency:

On patient with moderate renal insufficiency, dosage must be reduced 50% from recommendation dose. Diacerein is contraindicated on patient with severe renal insufficiency.

Hepatic insufficiency:

It does not found significant deviation for pharmacokinetic parameter on patient with cirrhosis hepatic with mild or severe hepatic insufficiency and it did not need adjusted dose for this patient.

But, Diacerein is contraindicated on patient with severe liver functions.


Presentation and Registration Number :

ACETRO® Capsule Box, 3 strips @ 10 capsule; DKL1708024801A1




Categorised in:

This post was written by admin